CatSci expands focus to lead optimisation

The contract research organisation has increased its focus on the beginning stages of drug discovery and development

CatSci has expanded its focus to a wider range of drug pipeline stages. The Welsh contract research organisation (CRO) has traditionally focused on the later stages of drug discovery and development, but now it also offers services in lead optimisation.

Speed is essential in pharmaceutical discovery and development to get the drug to market, maximise the patent life and bring new therapies to patients. Working with the same company streamlines the process from lead optimisation through product launch, enabling the compounds to move along the pipeline faster.

Commenting on the announcement Dr Paul Bradley, Head of Business Development at CatSci, said: “This is an important step for CatSci as we continue our rapid expansion. Delivering quality lead optimisation projects for our customers will answer the demands of both the US and UK markets, increase our customer base and lead to long term growth for the company.”

This expansion enables CatSci to broaden its customer base and create more jobs in Wales, recruiting and training chemists educated to PhD level.

Companies